KR920703597A - 항종양성 물질 be-13793c - Google Patents

항종양성 물질 be-13793c

Info

Publication number
KR920703597A
KR920703597A KR1019920700375A KR920700375A KR920703597A KR 920703597 A KR920703597 A KR 920703597A KR 1019920700375 A KR1019920700375 A KR 1019920700375A KR 920700375 A KR920700375 A KR 920700375A KR 920703597 A KR920703597 A KR 920703597A
Authority
KR
South Korea
Prior art keywords
substance
acceptable salt
tumor
streptomyces
mutant
Prior art date
Application number
KR1019920700375A
Other languages
English (en)
Other versions
KR0163202B1 (ko
Inventor
가추히사 고지리
히로유키 수다
아키라 오쿠라
마사노리 오카니시
겐지 가와무라
Original Assignee
도야마 노리유키
반유 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 도야마 노리유키, 반유 세이야쿠 가부시키가이샤 filed Critical 도야마 노리유키
Publication of KR920703597A publication Critical patent/KR920703597A/ko
Application granted granted Critical
Publication of KR0163202B1 publication Critical patent/KR0163202B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/625Streptoverticillium
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/908Streptovirticillium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

내용 없음

Description

항종양성 물질 BE-13793C
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기 구조식의 항종양성 물질 BE-13793C 또는 이의 약제학적으로 허용되는 염.
  2. 활성 성분으로서, 하기구조식의 항종양성 물질 BE-13793C 또는 이의 약제학적으로 허용되는 염을 유효량 포함하는 항종양제.
  3. 하기 구조식의 항종양성 물질 BE-13793C를 제공할 수 있는 미생물 또는 이의 돌연변이체를 배양하고, 이렇게 하여 모아진 항종양성 물질 BE-13793C를 회수함을 특징으로 하여, 항종양성 물질 BE-13793C 또는 이의 약제학적으로 허용되는 염을 제조하는 방법.
  4. 제3항에 있어서,스트렙토베르티실리움종 (Streptoverticilliumsp.) BA - 13793 균주 또는 이의 돌연변이체를 배양하는 방법.
  5. 항종양성 물질 BE-13793C를 제공하며스트렙토베르티실리움(Streptoverticillium)속 또는 이의 돌연변이체에 속하는 미생물.
  6. 제5항에 있어서,스트렙토베르티실리움종 BA - 13793 균주 또는 이의 돌연변이체인 미생물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920700375A 1989-03-23 1990-06-20 항종양성 물질 be-13793c KR0163202B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7114989 1989-03-23
PCT/JP1990/000812 WO1991019716A1 (en) 1989-03-23 1990-06-20 Antitumor substance be-13793c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019980703857A Division KR0177585B1 (ko) 1998-05-23 1990-06-20 항종양성 물질 b e-13793c-생성 균주

Publications (2)

Publication Number Publication Date
KR920703597A true KR920703597A (ko) 1992-12-18
KR0163202B1 KR0163202B1 (ko) 1998-12-01

Family

ID=13452261

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920700375A KR0163202B1 (ko) 1989-03-23 1990-06-20 항종양성 물질 be-13793c

Country Status (13)

Country Link
US (2) US5106864A (ko)
EP (1) EP0388956B1 (ko)
JP (1) JP3010675B2 (ko)
KR (1) KR0163202B1 (ko)
AT (1) ATE110727T1 (ko)
AU (1) AU634247B2 (ko)
CA (1) CA2012955C (ko)
DE (1) DE69011913T2 (ko)
DK (1) DK0388956T3 (ko)
ES (1) ES2063186T3 (ko)
HU (1) HU210868A9 (ko)
NO (1) NO300812B1 (ko)
WO (1) WO1991019716A1 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0528030B1 (en) * 1990-05-11 1997-09-17 Banyu Pharmaceutical Co., Ltd. Antitumor be-13793c derivative
US5478813A (en) * 1990-05-11 1995-12-26 Banyu Pharmaceutical Co., Ltd. Antitumor substance BE-13793C derivatives
US5591842A (en) * 1991-11-29 1997-01-07 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
US5589365A (en) * 1991-11-29 1996-12-31 Banyu Pharmaceutical Co., Ltd. Process for producing glycosylated indolopyrrolocarbazole derivatives by culturing certain microorganisms
US5668271A (en) * 1991-11-29 1997-09-16 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
EP0630242B1 (en) * 1992-03-20 1999-01-20 The Wellcome Foundation Limited Further indole derivatives with antiviral activity
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
US5922860A (en) * 1994-05-09 1999-07-13 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
US5804564A (en) * 1994-05-09 1998-09-08 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
WO1995034663A1 (fr) * 1994-06-13 1995-12-21 Banyu Pharmaceutical Co., Ltd. Gene codant la glycosyl-transferase et utilisation de ce gene
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
WO1997029205A1 (en) * 1996-02-07 1997-08-14 Banyu Pharmaceutical Co., Ltd. Effective production method of be-13793c
GB9811624D0 (en) * 1998-05-29 1998-07-29 Merck Sharp & Dohme Therapeutic use
WO2004083228A1 (ja) 1999-09-10 2004-09-30 Katsuhisa Kojiri インドロピロロカルバゾール誘導体及び抗腫瘍剤
FR2845996A1 (fr) * 2002-10-16 2004-04-23 Servier Lab Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE102006038635B4 (de) * 2006-08-19 2010-04-15 Josip Marinic Magnettonabnehmer für ein Saiteninstrument
JP7019601B2 (ja) 2016-07-12 2022-02-15 カリフォルニア インスティチュート オブ テクノロジー 高密度細胞増殖と代謝産物交換のための基材

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0826037B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質k−252の誘導体
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel

Also Published As

Publication number Publication date
NO920614L (no) 1992-03-24
CA2012955A1 (en) 1990-09-23
WO1991019716A1 (en) 1991-12-26
EP0388956A3 (en) 1991-10-02
EP0388956B1 (en) 1994-08-31
NO300812B1 (no) 1997-07-28
HU210868A9 (en) 1995-08-28
ATE110727T1 (de) 1994-09-15
DE69011913D1 (de) 1994-10-06
NO920614D0 (no) 1992-02-17
ES2063186T3 (es) 1995-01-01
AU634247B2 (en) 1993-02-18
DE69011913T2 (de) 1995-02-09
JPH0320277A (ja) 1991-01-29
CA2012955C (en) 2001-08-21
JP3010675B2 (ja) 2000-02-21
DK0388956T3 (da) 1994-11-14
US5290698A (en) 1994-03-01
US5106864A (en) 1992-04-21
AU5835190A (en) 1992-01-07
EP0388956A2 (en) 1990-09-26
KR0163202B1 (ko) 1998-12-01

Similar Documents

Publication Publication Date Title
KR920703597A (ko) 항종양성 물질 be-13793c
ES466791A1 (es) Procedimiento para la produccion de esterastina.
AU4921590A (en) Pf 1022 substance, method of producing same and anthelmintic composition containing same
KR910009729A (ko) 신규한 폴리펩티드 화합물과 그 제조방법
AU565322B2 (en) Substances from actinomadura strains
KR940014800A (ko) 인돌로피롤로카르바졸 유도체의 제조방법
KR900016264A (ko) 항생제 tan-1057
KR870004144A (ko) 항종양 항생제(ll-e33288 복합체)의 제법
IE37331L (en) Production of saccharase inhibitor
US2917435A (en) Preparation of 2-keto-1-gulonic acid by pseudomonas aeruginosa
KR890014457A (ko) 신규 아족시 화합물 및 그의 제조방법
DE68916659T2 (de) WS-9326 A, WS-9326B und deren Derivate.
CA2059632A1 (en) Reveromycin a, method for preparing same, and antitumor agent and antifungal agent comprising the same
KR910014398A (ko) 항생제 데옥시물룬도칸딘, 이의 제조방법 및 약제로서의 이의 용도
KR910003113A (ko) 항생물질 플러스박신
KR900006517A (ko) 항생제 pb-6042류
KR910016916A (ko) 미생물 및 이를 이용한 바이오틴 바이타머의 생산방법
BR9204844A (pt) Antibiotico ab-041,processo para sua preparacao,microorganismo,cultura biologicamente pura do microorganismo streptomyces sp.ncimb 40428 ou de um mutante equivalente,composicoes herbicidas,e,processo de retardar o crescimento de gramineas que infestam as plantacoes
KR910009728A (ko) 폴리펩티드 화합물과 그 제조방법
KR910014509A (ko) 항생성 알리사마이신, 이의 제조방법 및 용도
KR880002995A (ko) 푸럭토 올리고(Fructo-oligo)당의 제조방법
KR900018384A (ko) 항생제 아라노로신, 이의 미생물학적 제조방법 및 이의 약제로서의 용도
DE69008400T2 (de) Herstellung von 2-Desoxyuridin.
KR910012257A (ko) 벤즈안트라센 화합물 및 이의 제조방법
MY105945A (en) Process for producing l-glutamic acid.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060824

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee